Opportunistic Infection in Hospitalised Patients with Inflammatory Bowel Disease

Jin-Qiu Zhou¹, Zhang-Min Meng¹, Tao Zhang², Xing-Tao Jing³ and Hua-Tian Gan¹

¹Department of Geriatrics Medicine and the Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China

²Department of Gastroenterology, Nanchong Central Hospital, Nanchong, Sichuan, China

³Department of Otolaryngology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

ABSTRACT

Objective: To investigate the incidence, clinical features, and risk factors of opportunistic infections in elderly patients with inflammatory bowel disease (IBD).

Study Design: Observational study.

Place and Duration of Study: Department of Digestive and Geriatrics Center, Sichuan University West China Hospital, China between January 2012 and January 2019.

Methodology: Patients (≥ 18 years) with IBD were enrolled in this study. Clinical data from the infected elderly group (age ≥ 60 years), non-infected elderly group (age ≥ 60 years) and infected adult group (age: 18-59 years) were compared. Logistic regression analysis was used for risk factors associated with opportunistic infection.

Results: A total of 8.9% (307/3,456) of patients with IBD had opportunistic infection. The opportunistic infection rate of elderly group was 16.5% (80/485), which was significantly higher than that of adult group (7.6%, 227/2,971, $p < 0.05$). Compared with infected adult group or non-infected elderly group, infected elderly group had less fever and leukocytosis, but more hypoproteinemia and several activities ($p < 0.05$). Cytomegalovirus and Epstein-Barr virus were the most common agents in elderly group and adult group, respectively. Multiple episodes (three or more) were more common in infected elderly group; the time of opportunistic infections was associated with systemic inflammatory reaction syndrome (SIRS, $p < 0.05$). Logistic regression analysis showed that age ≥ 60 years, corticosteroids, immunosuppressive and biological agents were risk factors for opportunistic infections in patients with IBD.

Conclusion: Hospitalised elderly IBD patients, receiving corticosteroids, immunosuppressive, and biological agents, are at higher risk for infection. The symptoms of opportunistic infections in elderly patients are atypical, but they are prone to multiple infections with poor prognosis.

Key Words: Elderly patients, Inflammatory bowel disease, Opportunistic infection, Systemic inflammation reaction syndrome.

How to cite this article: Zhou JQ, Meng ZM, Zhang T, Jing XT, Gan HT. Opportunistic Infection in Hospitalised Patients with Inflammatory Bowel Disease. *J Coll Physicians Surg Pak* 2020; **30**(10):1015-1020.

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting disease, mainly including Crohn's disease (CD) and ulcerative colitis (UC), and the incidence rate is increasing throughout Asia.^{1,2}

A bimodal age curve for IBD incidence has been suggested in epidemiological studies, with the first peak occurring at 20-30 years and a second small peak occurring at 60-70 years, correlating with the approximately 10-15% of cases that manifest after the age of 60 years.³ Along with the worsening increase in population aging, IBD will become an increasingly serious problem among elderly patients, by affecting their quality of life and even life expectancy. Corticosteroids, immunosuppressants, and biologic medications can be used alone or in combination to treat patients with moderate to severe IBD. Each treatment strategy can effectively combat the disease, but increase the risk of opportunistic infection.⁴ Elderly patients are at higher risk of opportunistic infection due to a low level of immunity, impaired intestinal mucosal barrier function, malnutrition, and intestinal flora imbalances.⁴⁻⁸ Previous study indicated that IBD patients (65 years or older) had 2-to-3 fold increased infection risks compared with younger patients with IBD.⁹

Correspondence to: Hua-Tian Gan, Department of Geriatrics Medicine and the Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu 61004, China

E-mail: zhoujinqu13@163.com

Received: July 25, 2020; Revised: October 06, 2020;

Accepted: October 19, 2020

DOI: <https://doi.org/10.29271/jcpsp.2020.10.1015>

Table I: Comparison of clinical characteristics between infected elderly group and infected adult group/non-infected elderly group.

	Infected elderly group (n=80)	Infected adult group (n=227)	Non-infected elderly group (n=405)	P1*	P2*
Sex, male/female, N	50(62.5%)/30(37.5%)	132(58.1%)/95(41.9%)	235(58.0%)/170(42.0%)	0.496	0.457
Age, (mean±SD) (years)	68.59±6.63	36.09±12.20	66.72±8.26	<0.001	0.050
UC/CD, N	68(85.0%)/12(15.0%)	130(57.3%)/97(42.7%)	350(86.4%)/55(13.6%)	<0.001	0.737
Hospitalization days {median (IQR)} (days)	19(17-23)	17(15-20)	16(12-19)	<0.001	<0.001
Expense {median (IQR)} (Yuan,RMB)	12301.21(8033.73-25591.79)	11340.12(5776.94-18621.70)	10653.92(7497.06-16720.47)	0.041	0.047
Fever, N(%)	24(30.0%)	98(43.2%)	72(17.8%)	0.038	0.012
Diarrhoea, N(%)	67(83.8%)	192(84.6%)	296(73.1%)	0.860	0.045
Abdominal pain, N(%)	58(72.5%)	190(83.7%)	258(63.7%)	0.029	0.131
Abdominal distension, N(%)	64(80.0%)	160(70.5%)	275(67.9%)	0.099	0.031
Abdominal mass, N(%)	4(5.0%)	26(11.5%)	20(4.9%)	0.095	>0.999
Anemia (<120g/l), N(%)	51(63.8%)	173(76.2%)	230(56.8%)	0.031	0.249
Hypoproteinemia (<35.0g/L), N(%)	53(66.3%)	119(52.4%)	190(46.9%)	0.032	0.002
Platelet increase (>300 10A9/L), N(%)	19(23.8%)	91(40.1%)	60(14.8%)	0.009	0.048
Leukocyte increase(>9.5 10A9/L), N(%)	22(27.5%)	92(40.5%)	99(24.4%)	0.038	0.564
ESRa increase (>15 mm/L), N(%)	55/66(83.3%)	151/172(87.8%)	195/320(60.9%)	0.367	0.001
CRPB increases (>5 mg/L), N(%)	46/66(69.7%)	128/172(74.4%)	162/320(50.6%)	0.462	0.005
PCTc increases (>5 mm/L),N(%)	23/32b(71.9%)	72/90b(80.0%)	50/120b(41.7%)	0.342	0.002
Clinical disease activities					
Mild, N(%)	0(0.0%)	2(0.88%)	15(3.7%)	>0.999	0.147
Moderate, N(%)	18(22.5%)	77(33.9%)	151(37.3%)	0.057	0.011
Severe, N(%)	62(77.5%)	148(65.2%)	239(59.0%)	0.042	0.002

*P1: P-value of the infected elderly group compared with the infected adult group; P2: P value of the elderly infected group compared with the infected non-infected group. ^aBlood sedimentation rate (ESR) and ^bC-reactive protein (CRP) tests were performed in 66 patients of infected elderly group, 172 patients of infected adult group and 320 patients of non-infected elderly group. ^cProcalcitonin (PCT) was performed in 32 patients of infected elderly group, 90 patients of infected adult group and 120 patients of non-infected elderly group. ^dClinical disease activities: Mayo Clinic score for ulcerative colitis (UC), Crohn's disease activity index for Crohn's disease(CD).

Table II: Comparison of pathogens between infected elderly group and infected adult group.

N (%)	Infected elderly group (n=80)	Infected adult group (n=227)	p
Virus	53(66.3%)*	160(70.5%)*	0.480
Cytomegalovirus (CMV)	30(37.5%)	75(33.0%)	
Epstein-Barr virus (EBV)	30(37.5%)	82(36.1%)	
Other viruses ^a	10(12.5%)	23(10.1%)	
Hepatitis virus	3(3.75%)	8(3.5%)	
Bacterial	36(45.0%)	74(32.6%)	0.047
Other Bacteriac ^b	26(32.5%)	34(15.0%)	
Clostridium difficile(CDI)	9(11.3%)	30(13.2%)	
Tuberculosis	2(2.5%)	10(4.4%)	
Fungal and Parasite	10(12.5%)	20(8.8%)	0.339
Coinfection with different pathogens (≥2 species)	19(23.8%)	31(13.7%)	0.036

^aOther viruses: Herpes simplex virus, Varicella-zoster virus, etc. ^bOther bacteriac: Streptococcus pneumoniae, Escherichia coli, etc.

Table III: Univariate analysis and multivariate analysis of risk factors for opportunistic infection in IBD patients.

	p-value	Odds ratio	95%CI	p-value	Odds ratio	95%CI
Gender: Man	0.144	0.625	0.333-1.174	-	-	-
Age >60 years	0.043	2.086	1.023-4.253	0.029	2.542	1.100-5.875
Smoking	0.423	1.216	0.754-1.962	-	-	-
Aminosalicic acid	0.073	2.017	0.937-4.339	-	-	-
Corticosteroids	0.004	2.513	1.344-4.699	0.028	2.133	1.086-4.191
Immunosuppressants	<0.001	3.335	1.763-6.311	<0.001	3.612	1.804-7.234
Biological agents	<0.001	4.353	1.926-9.838	0.003	3.772	1.565-9.093
Hypertension	0.469	1.619	0.439-5.968	-	-	-
Diabetes	0.021	3.810	1.218-11.913	0.076	3.319	0.885-11.127
COPD	0.356	2.156	0.422-11.011	-	-	-

COPD: Chronic obstructive pulmonary disease

This is an important issue, as there is an increased difficulty in the diagnosis and management of elderly IBD with oppor-

tunistic infection. Unfortunately, research regarding elderly IBD patients with opportunistic infection in China has been deficient. In this study, the aim was to investigate clinical features, the frequency of and risk factors of opportunistic infections in elderly patients with IBD.

METHODOLOGY

Patients of 18 years or older identified with IBD at Sichuan University, West China Hospital from January 2012 to January 2019, were included in this observational cohort study. The information of cases was obtained from the inpatient information database and the electronic management inquiry system of three institutions. This study has passed the biomedical ethics review of West China Hospital of Sichuan University (approval number: 2018242). This is an observational study, and informed consent has been exempted by using the medical records obtained from previous clinical diagnosis and treatment. Patients were diagnosed with IBD according to established clinical, endoscopic, and histological criteria. According to the ICD-10 codes of CD or UC of inpatient, the identification of patients has been confirmed.

Patients with IBD, also suffering from acquired immune deficiency syndrome (AIDS), congenital immunodeficiency, or organ transplantation were excluded. Opportunistic infections were classified based on pathogens, including viral [e.g., cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV)], *Escherichia coli*, *Streptococcus pneumoniae*, *Clostridium difficile* (CDI), *Mycobacterium tuberculosis*, fungal (e.g., *Candida*, *Histoplasma*), and parasitic infections. Supplementary file provided the diagnoses of opportunity infection according to the infection sites and pathogens, and the ICD-10 of pathogens.

According to age and opportunity infection, patients were divided into an infected elderly group and a non-infected elderly group (age ≥ 60 years), and an infected adult group and a non-infected adult group (age 18-59 years). The infected elderly group was finally divided into a parenteral infection group and an intestinal infection group.

Clinical and analytical data, obtained from the patients, included their gender, current age, the type of IBD (UC or CD), length of hospital stay, treatment expense, clinical feature, laboratory examination, infection pathogens (for infection patients), medical treatments and the prognosis. This data were compared between infected elderly group and non-infected elderly group; infected elderly group and infected adult group.

The disease activity was evaluated by the Mayo score for UC¹⁰ and Crohn's disease activity index (CDAI, for CD).¹¹ It was divided into clinical remission (Mayo < 3 , CDAI < 150), mild activity (Mayo 3-5, CDAI 150-220), moderate activity (Mayo 6-10, CDAI 221-450), and severe activity (Mayo 11-12,

CDAI > 450).

Systemic inflammatory reaction syndrome (SIRS) criteria are defined as a heart rate > 90 beats per minute, a respiratory rate > 20 breaths per minute, a temperature $< 36^{\circ}\text{C}$ or $> 38^{\circ}\text{C}$ and a white blood cell count $< 4000/\text{mm}^3$ or $> 12\,000/\text{mm}^3$. A positive score was defined as ≥ 2 out of 4.¹²

The quantitative variables with normal distribution are presented as the mean $\pm$ standard deviation (SD), those with skewed distribution as median (IQR), and categorical variables as number (percentage). For between-group comparisons, the Chi-square/Fisher's exact test was used for discrete variables, and independent sample t-test or Mann-Whitney U-test for continuous variables. Univariate regression and multivariate logistic regression analyses were performed to evaluate the risk factors for opportunistic infection. Correlations between ordered categorical variables were measured by *Kendall tau*. The results were considered significant when p was < 0.05 . All analyses were conducted using the SPSS, version 20.0 (SPSS, Inc., Chicago, Illinois, USA).

RESULTS

In this study, a total of 3,456 patients with IBD [1985 (57.4%) males and 1,471 (42.6%) females] with an average age of 41.6 ± 4.24 years were studied, including 80 (2.3%) infected elderly patients, 227 (6.6%) non-infected elderly patients, and 405 (11.7%) infected adult patients. Additionally, 307 (8.9 %) of 3,456 IBD patients had opportunistic infections. The infection rate of elderly patients was 16.5% (80/485), which was significantly higher than 7.6% (227/2971) of adult patients ($p < 0.001$). As shown in Table I, infected elderly group had longer hospital stay and more treatment costs compared with infected adult group and non-infected elderly group ($p < 0.05$). Compared with infected adult group, fever and abdominal pain were less common in the infected elderly group ($p < 0.05$). Compared with the non-infected elderly group, fever, diarrhea, and abdominal pain were more common in the infected elderly group ($p < 0.05$).

Fifty-three patients in the infected elderly group had hypoproteinemia (66.3%). This incidence of hypoproteinemia was higher than that in the infected adult group (52.4%) and non-infected elderly group (46.9%, $p < 0.05$). Compared with the infected adult group, the infected elderly group was less likely to have anemia, increased leukocyte count and platelet count ($p < 0.05$). Several activity of IBD were more frequent in infected elderly group than in infected adult group and in non-infected elderly group ($p < 0.05$).

As shown in Table II, viral infections were the most frequently occurring infectious agents in elderly (66.3%) and young (70.5%) patients with IBD. CMV infection was the most common in the infected elderly group (37.5%), while

EBV infection was the most common in the infected adult group (36.1%). The bacterial infection rate in the infected elderly group (45.0%) was higher than that in the infected adult group (32.6%, $p < 0.05$). Elderly IBD patients were more likely to have multiple pathogen (two pathogens or more) infections compared with young IBD patients ($p < 0.05$). For infected elderly patients, there were 24 patients in intestinal infection group and 56 patients in parenteral infection group. The infection rate was 11.5% (56/485) in the parenteral infection group, as compared to 4.9% (24/485) in the intestinal infection group ($p < 0.001$). In addition, we found a significant association between parenteral infection group and several activity of IBD in elderly infected group (Kendall's tau-a = 0.265, $p = 0.017$), but no significant association was found in adult infected group (Kendall's tau-a = 0.106, $p = 0.110$).

Seventy-five percent (60/80) of elderly infected patients and 82.4% (187/227) of young infected patients had a stable response, but 23.8% (19/80) of elderly infected patients and 17.6% (40/227) of young infected patients had SIRS. One elderly infected patient did not achieve remission, progressively deteriorated, and died during the course of therapy. There was no significant difference in the clinical remission rates (infected elderly group versus infected adult group, 75.0% vs. 82.4%, $p = 0.152$), SIRS rates (infected elderly group versus infected adult group, 23.8% vs. 17.6%, $p = 0.232$), death rates (infected elderly group versus infected adult group, 1.3% vs. 0.0%, $p = 0.261$) with two groups. Figures 1 and 2 show opportunistic infections (≥ 3 times) was much more common in infected elderly group than in infected adult group (8.8% vs. 2.2%, $p = 0.016$). The times of opportunistic infections may be associated with the incidence of SIRS in elderly infected group (Kendall's tau-a = 0.291, $p = 0.008$). In regression analysis, elderly patients, who suffered two times of opportunistic infections, have 3.556 times the SIRS risk of those who suffered one times of opportunistic infections (OR 3.556; 95% CI: 1.014-12.467, $p = 0.048$); elderly patients who suffered their times of opportunistic infections have 5.333 times the SIRS risk of those who suffered one times of opportunistic infections (OR 5.333; 95% CI: 1.123-25.331, $p = 0.035$). However, no correlation was found between the times of opportunistic infections and SIRS in young elderly group (Kendall's tau-a = 0.111, $p = 0.091$).

As Table III indicates, multivariate regression showed that age ≥ 60 years ($p = 0.029$, or $p = 2.542$), corticosteroids ($p = 0.028$, OR = 2.133), immunosuppressants ($p < 0.001$, OR = 3.612) and biological agents ($p = 0.003$, or $p = 3.772$) were independent risk factors for IBD patients. Patient's gender, smoking habit, use of aminosalicylic acid, and presence of hypertension and diabetes were not associated with an increased risk of opportunistic infection in multivariate regression.

Figure 1: Comparison between in the infected elderly group and infected adult group in the times of opportunistic infection.

^a $p=0.004$ versus infected adult group (1 time of opportunistic infection); ^b $p=0.086$ versus infected adult group (2 times of opportunistic infection); ^c $p=0.016$ versus infected adult group (≥ 3 times of opportunistic infection).

Figure 2: Comparison of prognosis between in the infected elderly group and infected adult group.

^a $p=0.152$, versus infected adult group in Remission rates; ^b $p=0.232$, versus infected adult group in SIRS rates; ^c $p=0.261$ versus infected adult group in death rates.

DISCUSSION

Patients with IBD have a high risk of opportunistic infections, and the prevalence of opportunistic infections has been reported to be much higher in elderly IBD patients than young IBD patients.^{9,13,14} Previous domestic reports have indicated that the opportunistic infection rate is about 15.0% in hospitalised IBD patients (age > 50 years).⁹ This study found that the opportunistic infection rate of elderly hospitalised patients (16.5%), which is significantly higher than that of young hospitalised patients (7.6%), and that age ≥ 60 years is an independent risk factor of opportunistic infection. The reasons for the increased risk of opportunistic infection in elderly IBD patients are varied, but the main reason is that elderly patients have a decreased immune function because of aging. It leads to a decrease in the number of haematopoietic stem cells results in downstream thymic atrophy and decrease number and functional status of B-lymphocyte and T-lymphocyte.^{7,15,16} Furthermore, treatment with corticosteroids, immunosuppressants, biological agents and malnutri-

tion were also important drivers of opportunistic infection caused by decreased immune function.⁵

In this study, most of elderly infected patients had atypical clinical presentation. Elderly IBD patients often developed opportunistic infection without fever and leukocytosis, but they are prone to diarrhea, hypoproteinemia and several activity of IBD. There was a positive relationship between parenteral infection and several IBD in elderly patients. The IBD patients, who were accompanied by concomitant bloodstream and pulmonary infection, may have weakened immunity, aggravating the IBD.^{9,13} This finding indicates that for elderly IBD patients, one should have high suspicion for opportunistic infection when IBD disease has several activities even in the absence of fever and leukocytosis. Hypoproteinemia, which might be caused by worsening diarrhea and hematochezia with opportunistic infection, was more prevalent in infected elderly group in this study. However, hypoproteinemia and malnutrition may bring damage to complement system, lower the level of protein, and weaken the immunity.¹⁷ This makes them more vulnerable to opportunistic infections. So, between malnutrition and opportunistic infection, this may be a vicious cycle. Appropriate nutritional support, together with the conventional treatment, is particularly important for elderly IBD patients with opportunistic infection.

Viral infections were frequently observed in IBD patients (more than 60%) and elderly IBD patients were at a higher risk of CMV infection, which was consistent with previous studies.¹⁸ This may be because TNF- α expressed in UC activates CMV, while IFN- γ expressed in CD inhibits CMV.^{18,19} In previous study, UC was observed more frequently than CD in elderly patients. So elderly patients are more susceptible to CMV infection.¹⁹ Concurrent corticosteroid use and hospitalisation within one month were associated with CDI.²⁰ In this study, CDI mainly infects the intestines and occurred in 37.5% elderly IBD patients, who had a longer hospital stay (about 21 days on average) and higher risk of opportunistic infection when treated with corticosteroid. It is, therefore, suggested that those elderly patients have long hospital stay with corticosteroid therapy, under the monitor of the CDI infection.

Although no statistical difference was found in remission and SIRI rates between elderly and young infected patients, elderly patients were more likely to have multiple infections, and the times of opportunistic infections was associated with SIRI. This means that for elderly IBD patients, the higher the number of infections, the worse the prognosis. In addition, the use of corticosteroids, immunosuppressants, and biological agents was also the risk factors of opportunistic infection in patients with IBD, which was consistent with previous studies.^{13,21} These treatments work in different ways and mechanisms, but all may alter immune responsiveness to varying degree.⁵ Immunosuppressants can selectively inhibit the activation and proliferation of lymphocytes, decrease the expression of proinflammatory cytokines, and azathioprine or 6-Mercaptopurine can inhibit de novo synthesis of RNA and DNA.^{22,23} When corticosteroids are used in large amounts or for longer period

of time, the number of B-lymphocytes in the spleen and lymph nodes decrease remarkably, immunoglobulin degradation is increased, and synthesis is inhibited.²⁴ Additionally, TNF-inhibitors play an anti-inflammatory role by blocking TNF- α from binding to its cell surface receptors and promoting the apoptosis of inflammatory cells, though they might increase the risk of opportunistic infections.²⁵

However, there were some limitations in this study. Firstly, the population were all inpatients and the three institutions were all tertiary referral hospitals, which tend to see sicker patients with IBD, and there may be selective bias. Secondly, IBD patients younger than 18 years were not included, so the difference between elderly IBD patients and younger IBD patients (<18 years) with opportunistic infection was not clear.

CONCLUSION

Elderly IBD patients are at higher risk of opportunistic infection due to decreased immunity, malnutrition and the use of corticosteroids or immunosuppressants. The atypical clinical manifestations of infection and poor prognosis not only increase the difficulty of diagnosis and treatment, but also increase health-care burden. Thus, clinician should pay attention to this activity. Therefore, it is important to closely monitor elderly patients to enable early detection and management of opportunistic infection, and to provide appropriate nutritional support.

DISCLOSURE:

The present work was supported by the National Natural Science Foundation of China (No 81470826), the Science Foundation from Science & Technology Department of Sichuan Province (No. 2019YFS0262); and 1.3.5 Project For Disciplines Of Excellence, West China Hospital, Sichuan University (No.ZYGD18023).

ETHICAL APPROVAL:

Ethics Committee approval was received from the Ethics Committee of West China Hospital of Sichuan University (Number: 2018242).

PATIENTS' CONSENT:

Informed consents were obtained from all participants or their family.

CONFLICT OF INTEREST:

The authors declared no conflict of interest.

AUTHORS' CONTRIBUTION:

JQZ: Conception and design, data acquisition and analysis, interpretation, drafting, final approval.

ZMM: Design, critical revision, final approval.

TZ: Interpretation, critical revision, final approval.

XTJ: Analysis and interpretation, drafting, final approval.

HTG: Conception and design, interpretation, critical revision, final approval.

REFERENCES

1. Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory

- bowel disease and the elderly: a review. *J Crohns Colitis* 2015; **9(6)**:507-15. doi: 10.1093/ecco-jcc/jjv059.
2. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: Comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. *Dig Dis Sci* 2013; **58(5)**:1306-12. doi: 10.1007/s10620-012-2517-5.
 3. Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. *J Crohns Colitis* 2011; **5(1)**:5-13. doi: 10.1016/j.crohns.2010.08.004.
 4. Wheat CL, Ko CW, Clark-Snustad K, Grembowski D, Thornton TA, Devine B. Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis. *BMC Gastroenterol* 2017; **17(1)**:52. doi: 10.1186/s12876-017-0602-0.
 5. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014; **8(6)**:443-68. doi: 10.1016/j.crohns.2013.12.013.
 6. Gauss A, Rosenstiel S, Schnitzler P, Hinz U, Rehlen T, Kadmon M, et al. Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease: A 10-year tertiary referral center experience. *Eur J Gastroenterol Hepatol* 2015; **27(6)**:712-20. doi: 10.1097/MEG. 0000000000000361.
 7. Weng NP. Aging of the immune system: how much can the adaptive immune system adapt? *Immunity* 2006; **24(5)**:495-9. doi: 10.1016/j.immuni.2006.05.001.
 8. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. *J Histochem Cytochem* 2008; **56(3)**:267-74. doi: 10.1369/jhc.7A7303.2007.
 9. Kirchgessner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. *Gastroenterology* 2018; **155(2)**:337-346.e10. doi: 10.1053/j.gastro.2018.04.012.
 10. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. *Gastroenterology* 2007; **132(2)**:763-86. doi: 10.1053/j.gastro.2006.12.038.
 11. Best WR, Beckett JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; **70(3)**:439-44. PMID: 1248701.
 12. Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. *N Engl J Med* 2015; **372(17)**:1629-38. doi: 10.1056/NEJMoa1415236.
 13. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. *J Gastroenterol* 2013; **48(5)**:595-600. doi: 10.1007/s00535-012-0686-9.
 14. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* 2008; **134(4)**:929-36. doi: 10.1053/j.gastro.2008.01.012.
 15. Nguyen QP, Deng TZ, Witherden DA, Goldrath AW. Origins of CD4+ circulating and tissue-resident memory T-cells. *Immunology* 2019; **157(1)**:3-12. doi: 10.1111/imm.13059.
 16. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses. *Exp Gerontol* 2019; **124**:110632. doi: 10.1016/j. exger.2019.110632.
 17. Alwarawrah Y, Kiernan K, MacIver NJ. Changes in Nutritional Status Impact Immune Cell Metabolism and Function. *Front Immunol* 2018; **9**:1055. doi: 10.3389/fimmu.2018.01055.
 18. Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, et al. Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry. *J Crohns Colitis* 2016; **10(2)**:176-85. doi: 10.1093/ecco-jc-c/jjv194.
 19. Nakase H, Yoshino T, Honzawa Y, Chiba T. Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection. *Dig Dis Sci* 2010; **55(5)**:1498-9. doi: 10.1007/s10620-010-1162-0.
 20. Li Y, Xu H, Xu T, Xiao M, Tang H, Wu D, et al. Case-Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus. *Dig Dis Sci* 2018; **63(11)**:3074-3083. doi: 10.1007/s10620-018-5230-1.
 21. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. *Am J Gastroenterol* 2013; **108(8)**:1268-76. doi: 10.1038/ajg. 2013.138.
 22. Lee RA, Gabardi S. Current trends in immunosuppressive therapies for renal transplant recipients. *Am J Health Syst Pharm* 2012; **69(22)**:1961-75. doi: 10.2146/ajhp110624.
 23. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Purine Analogues 2014 Jul 14. PMID: 31643909.
 24. Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger CM, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn's disease. *Clin Gastroenterol Hepatol* 2015; **13(7)**:1293-1301.e5; quiz e70, e72. doi: 10.1016/j.cgh.2015.02.017.
 25. Nakase H, Chiba T. TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. *Inflamm Bowel Dis* 2010; **16(4)**:550-1. doi: 10.1002/ibd.21047.

• • • • •